Weight-Loss Injections: Public Health Insurance Refuses Coverage — Parliament Divided
Ozempic and Wegovy are hailed as breakthroughs against obesity and heart disease, but millions of publicly insured individuals in Germany remain without access. The political debate is intensifying.
Blocked Since 2004: The Legal Ban on Prescriptions
Around 16 million people in Germany suffer from obesity, yet the medications that doctors and researchers are increasingly celebrating as a breakthrough remain unaffordable for most of those affected. Since a legal amendment in 2004, § 34 SGB V explicitly excludes weight-loss drugs from the benefits catalog of statutory health insurance (GKV). The Federal Joint Committee (G-BA) most recently confirmed this classification in March 2024: Wegovy remains a so-called lifestyle drug — not reimbursable.
New Study Data Changes the Argumentation
What is now reigniting the debate is reliable clinical data. The SELECT study, involving 17,500 obese patients without diabetes, showed that semaglutide — the active ingredient in Ozempic and Wegovy — reduced major cardiovascular events such as heart attack and stroke by 20 percent. The absolute risk reduction is 1.5 percent, and the Number Needed to Treat is 67. This is an order of magnitude that is considered clinically significant in cardiology.
The European Association for the Study of Obesity (EASO) has also updated its guidelines: Semaglutide and tirzepatide are now considered first-line treatments for obese patients with comorbidities such as diabetes or cardiovascular disease. For comparison: While older drugs like orlistat achieve an average weight reduction of 2.8 kg, semaglutide achieves over 10 kg, and tirzepatide even up to 16.5 kg — over a period of one to two years.
45.8 Billion Euros: The Insurers' Cost Argument
The health insurers primarily argue against reimbursement with an alarming calculation. The AOK Federal Association has calculated that a comprehensive GKV coverage of GLP-1 preparations could cost up to 45.8 billion euros annually — a sum that almost corresponds to the entire expenditure item for medical and psychotherapeutic services (47.1 billion euros in 2023). Even a reimbursement approach limited to severe cases would significantly burden the system.
For self-payers, the monthly costs range between 172 and over 400 euros, depending on the preparation and dosage. Privately insured individuals have it much easier: Many private health insurance providers reimburse the drugs at least partially.
Two-Tier Medicine in Parliament
It is precisely this inequality that has fueled the political debate in the Bundestag. FDP health politician Andrew Ullmann demands that GLP-1 preparations no longer be regarded as lifestyle drugs, but as part of a medically indicated treatment approach for severe obesity. CDU representative Tino Sorge agrees — reimbursement must be examined if effectiveness is proven. The SPD remains cautious: In view of the financial situation of the GKV, a general entitlement to reimbursement is not justifiable, according to health politician Heike Baehrens.
Experts advocate a differentiated approach: Reimbursement only for severe obesity (BMI ≥ 35) with proven comorbidities such as type 2 diabetes or increased cardiovascular risk — combined with mandatory lifestyle changes. A realistic political solution is not expected until 2026 or 2027 at the earliest.
Conclusion: Medicine Advances, Politics Lags Behind
The scientific evidence for GLP-1 receptor agonists is stronger today than ever before. The fact that an effective drug against a widespread disease that costs millions of people their lives is only accessible according to their financial means is described by a growing number of doctors and patient associations as a failure of health policy. The decision that the system makes — or does not make — will set standards for dealing with expensive innovations in medicine.
